Lilly Cancer Drug Gets Hesitant Support from FDA Panel

Source: Reuters

Jul 10, 2015

In an informal poll, an FDA advisory panel effectively supported approval of Eli Lilly & Co's experimental lung cancer drug, necitumumab.

In a 1,093-patient clinical trial, necitumumab improved overall survival by an average of 1.6 months but also increased the risk of blood clots and electrolyte imbalances, both dangerous and potentially fatal side-effects.

While the survival benefits of the drug are modest at best, the drug makes headway with a disease -- advanced squamous NSCLC -- that only has a five-year survival rate of less than 5 percent.

Read the Reuters article

Return to the Web Watcher Newsletter  

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments